Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 06
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Kura Oncology Inc
KURA
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$10.62
-0.03
-0.28%
Dern. MÀJ: Oct 6, 4:05 AM
$10.60
-0.05
-0.47%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Kura Oncology Financials
Kura Oncology (KURA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Kura Oncology Q2 EPS $(0.77) Beats $(0.87) Estimate, Sales $20.874M Miss $21.420M Estimate
Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.87) by 11.49 percent. This is a 2.67 percent decrease over losses of $(0.75) per share from the
Benzinga Newsdesk
PRO
Kura Oncology Q1 EPS $(0.83) Beats $(0.94) Estimate, Sales $18.265M Miss $18.513M Estimate
Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(0.94) by 11.7 percent. This is a 25.76 percent decrease over losses of $(0.66) per share from the
Benzinga Newsdesk
Earnings Scheduled For May 12, 2026
Benzinga Insights
Kura Oncology Q4 Earnings Summary & Key Takeaways
Benzinga Insights
PRO
Kura Oncology Q4 EPS $(0.92) Misses $(0.59) Estimate, Sales $17.336M Miss $53.554M Estimate
Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.59) by 56.2 percent. This is a 318.18 percent decrease over losses of $(0.22) per share from
Benzinga Newsdesk
Earnings Scheduled For March 5, 2026
Benzinga Insights
